Biopharma News

Sarilumab is an investigational, human monoclonal antibody intended for the treatment of patients with active, moderate-to-severe rheumatoid arthritis

The assets will broaden AmpliPhi's IP portfolio and speed the development of its phage therapies

Takeda intends to use the facility primarily for the manufacture of Entyvio (vedolizumab) and other biologic products.

The total investment is around a half billion euro.

Facility will manufacture biologics for clinical trials.

New offering incorporates clinical, commercial and regulatory insight to improve the probability of an asset’s commercial success.

The PnuBioVax vaccine contains heat shock proteins and multiple antigens produced by a modified form of S. pneumoniae, leading to a mechanism of action which is expected to be strain-independent.

Samsung Bioepis’ second immunology biosimilar approved, to be commercialized under partnership with Merck

The company showcases the innovative Syrina 2.25 auto-injector that brings the flexibility to design a unique form factor and also the full Syrina platform accommodating multiple primary containers and high viscous, high volume injections.

Supported by Phase III studies in moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis.

The projected FDA action date is 16 March 2016.

Coated stoppers for sensitive and high-value injectables.

First completed Phase III study of adalimumab biosimilar in the treatment of patients with moderate-to-severe RA.

The system offers parallel processing and walk-away control of 24 micro bioreactors.

Trastuzumab development and transfer for first Indonesian on-site production.

Raheen site will be largest capacity biopharmaceutical production facility in Ireland.

New S80 film features consistent cell growth, robustness and high quality.

Services include feasibility studies, process and analytical development and scale-up.

The plans include a multifunctional preclinical research facility and a state-of-the-art biologics manufacturing facility.

BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics.

The terms of the license cover commercial use of a genetically-engineered Chinese Hamster Ovary (CHO) cell line, developed by Horizon and adapted to manufacturing conditions by LakePharma.

The LakeCentre facility, located in Boulder, Colorado will increase manufacturing and production capacity to support the company’s extensive portfolio of biologics medicines.

The one-day conference, entitled “Safety and Efficacy — Clinical Trials Solutions”, will bring together experts from SGS Life Services and the wider pharmaceutical industry, to discuss advances in biopharmaceutical research and development and combine ...

Under the terms of the agreement, Aragen gains the rights to apply this technology to the development of recombinant cell lines with significantly enhanced commercial production levels compared to current methods.